280 related articles for article (PubMed ID: 9521772)
1. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.
Cameron CE; Ridky TW; Shulenin S; Leis J; Weber IT; Copeland T; Wlodawer A; Burstein H; Bizub-Bender D; Skalka AM
J Biol Chem; 1994 Apr; 269(15):11170-7. PubMed ID: 8157644
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
5. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Ridky TW; Kikonyogo A; Leis J; Gulnik S; Copeland T; Erickson J; Wlodawer A; Kurinov I; Harrison RW; Weber IT
Biochemistry; 1998 Sep; 37(39):13835-45. PubMed ID: 9753473
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional structures of HIV-1 and SIV protease product complexes.
Rose RB; Craik CS; Douglas NL; Stroud RM
Biochemistry; 1996 Oct; 35(39):12933-44. PubMed ID: 8841139
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
Heaslet H; Lin YC; Tam K; Torbett BE; Elder JH; Stout CD
Retrovirology; 2007 Jan; 4():1. PubMed ID: 17212810
[TBL] [Abstract][Full Text] [Related]
9. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.
Louis JM; Dyda F; Nashed NT; Kimmel AR; Davies DR
Biochemistry; 1998 Feb; 37(8):2105-10. PubMed ID: 9485357
[TBL] [Abstract][Full Text] [Related]
10. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
[TBL] [Abstract][Full Text] [Related]
12. Programming the Rous sarcoma virus protease to cleave new substrate sequences.
Ridky TW; Bizub-Bender D; Cameron CE; Weber IT; Wlodawer A; Copeland T; Skalka AM; Leis J
J Biol Chem; 1996 May; 271(18):10538-44. PubMed ID: 8631853
[TBL] [Abstract][Full Text] [Related]
13. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
Rose RB; Craik CS; Stroud RM
Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
[TBL] [Abstract][Full Text] [Related]
14. Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex.
Kumar M; Prashar V; Mahale S; Hosur MV
Biochem J; 2005 Jul; 389(Pt 2):365-71. PubMed ID: 15794743
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
16. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
[TBL] [Abstract][Full Text] [Related]
18. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors.
Mulichak AM; Hui JO; Tomasselli AG; Heinrikson RL; Curry KA; Tomich CS; Thaisrivongs S; Sawyer TK; Watenpaugh KD
J Biol Chem; 1993 Jun; 268(18):13103-9. PubMed ID: 8514751
[TBL] [Abstract][Full Text] [Related]
19. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
20. Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant.
Hong L; Hartsuck JA; Foundling S; Ermolieff J; Tang J
Protein Sci; 1998 Feb; 7(2):300-5. PubMed ID: 9521105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]